NY-PYRAMID-ANALYTICS
9.5.2022 13:02:12 CEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider – next-generation business analytics for the enterprise – announced today that it has closed a Series E funding round of $120 million, bringing the company’s total venture capital raise to more than $200 million. The round was led by H.I.G. Growth Partners , the dedicated growth capital investment affiliate of H.I.G. Capital, a leading global alternative investment firm with over $48 billion of equity capital under management1 , with the participation of Clal Insurance Enterprises Holdings, Kingfisher Capital, and General Oriental Investments. Early investors who participated in this new round are JVP , Maor Investments, Sequoia Capital , and Viola Growth .
Key Points:
- New capital will finance Pyramid’s continued innovation advantage and hyper growth.
- Decision intelligence pioneer raised $211 million to date, inclusive of the Series E.
- Scott Hilleboe , Co-Head, H.I.G. Growth Partners, joins the Pyramid Board of Directors.
- The Pyramid Decision Intelligence Platform ranked first for Augmented Analytics Use Case in the Gartner Critical Capabilities for Analytics and Business Intelligence Platforms, 2022.
- Pyramid is on an accelerated path to become the next analytics leader.
The $120 million round will be strategically invested to drive hyper growth and make Pyramid the next Analytics Leader by accelerating the company’s first-mover advantage in augmented analytics capabilities and the decision intelligence category. Pyramid will allocate funds to:
- Continuously innovate the Pyramid Decision Intelligence Platform to best serve the business analytics needs of our customers, continue to define the emerging decision intelligence market, and maintain a technology advantage over legacy business intelligence tools such as Microsoft Power BI, Qlik and Tableau.
- Expand the company’s global geographic presence, capture a larger share of the Total Addressable Market for analytics, and increase Channel partnerships with complementary technology companies , independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI).
- Enhance the Pyramid customer experience with unmatched service and support, learning and professional certification, and networking and community.
- Become the greatest employer brand in analytics to effectively hire, reward and retain the best talent, including customer success, marketing, sales, and software engineering and development.
Pyramid Backed by Global Investors Shaping the Future of Technology
H.I.G. Growth Partners’ portfolio companies represent leading companies in the SaaS, eCommerce, Healthcare and Technologies industries throughout North America, Europe, and Latin America. Clal Insurance Enterprises Holdings provides insurance and financial services in Israel. Geneva-based General Oriental Investments is the Investment Management arm of the Cavamont / Cavenham Group of Companies which invest worldwide in all asset classes.
Returning investors are JVP, Maor Investments, Sequoia Capital, and Viola Growth. JVP is a visionary venture capital firm that has been instrumental in building some of the world’s largest companies and facilitating 12 IPOs on NASDAQ. These include Qlik, an early entrant in the business intelligence market, launched in the United States by JVP. Viola Growth is a technology growth capital fund, focusing on investing in global companies at the expansion phase. Portfolio companies include Outbrain, Similarweb, and Trigo. Sequoia Capital is a renowned VC firm whose portfolio companies include Okta, Snowflake, and Zoom.
What is Decision Intelligence?
Decision Intelligence is the fast-emerging, next big innovation in analytics which will accelerate data-driven transformation. There is more data available for analytics than ever before. More people are interested in making decisions with data. More sophisticated analytics are in demand.
Decision Intelligence is designed to speed up insights, scale adoption, and simplify analytics. More people want and require access to data to make faster, more intelligent decisions. These include internal and external non-technical stakeholders. Decision Intelligence empowers anyone to make faster, more intelligent decisions. And that can change everything.
Decision Intelligence is the Next Big Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
$215.7 Billion Total Addressable Market
Worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a new update to the Worldwide Big Data and Analytics Spending Guide from International Data Corporation (IDC) . The forecast also shows that BDA spending will gain strength over the next five years as the global economy recovers from the COVID-19 pandemic. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period will be 12.8%.
Analyst Viewpoints
Pyramid’s Decision Intelligence strategy was described as evolutionary in a recent analyst report from 451 Research, part of S&P Global Market Intelligence . Pyramid Analytics Plants a Stake in the Decision Intelligence Ground , authored by Krishna Roy, Senior Research Analyst on the Data, AI & Analytics team at 451 Research, examines Pyramid’s Decision Intelligence Platform in the context of the emerging decision intelligence market which experts see as the next evolution in analytics and business intelligence (ABI).
Gartner ranked Pyramid first for Augmented Analytics in the Gartner Critical Capabilities for Analytics and Business Intelligence Platforms, 2022 . Gartner noted that the Pyramid Decision Intelligence Platform also “scored well across all four use cases” evaluated: Augmented Analytics; Enterprise Analytics; General Analytics; Visual Self-Service Analytics. Twenty (20) companies were evaluated on 12 Critical Capabilities, including Microsoft BI, Qlik, and Tableau.
The Pyramid Decision Intelligence Platform won the Dresner Advisory Services 2021 Technology Innovation Awards in seven of 12 Categories. The Technology Innovation Awards are presented to the top-ranked vendors in 12 Dresner Advisory 2021 Wisdom of Crowds® thematic market reports. The annual thematic studies are based on data collected from end-users and provide a real-world perspective on various technical capabilities related to Dresner’s annual research. Each report examines current deployment trends, user intentions, and industry capabilities.
BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category in its BARC BI & Analytics 22 Report . Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (top 22-33% or top 2 products) in its 6 peer groups in The BI & Analytics Survey 22.
Executive Quote
Omri Kohl , Chief Executive Officer and Co-Founder, Pyramid: “I am gratified and humbled by the confidence some of the world’s best technology investors have exhibited in Pyramid; the technology, company, and people. Overwhelming interest from the venture capital community underscores the importance of the problems we help our customers solve and the innovations we introduced to help enterprises in ways BI tools and legacy analytics could not.
“This milestone is a testament to the intellect and hard work of our employees across the globe, commitment of our partners, and trust and advocacy of our customers. All elements are in place to speed Pyramid down the path to being the next enterprise analytics leader.”
Investor Quotes
Scott Hilleboe, Co-Head, H.I.G. Growth Partners: “H.I.G. partners with industry-leading companies to drive transformative change. Pyramid is a model of transformation. The Pyramid Decision Intelligence Platform upended analytics and business intelligence (ABI) by redefining what’s possible when the power of data insights is available to everyone.
“H.I.G. is excited to partner with Pyramid in their next stage of growth. Pyramid drives exceptional ROI to customers by empowering them to make faster, more intelligent decisions leveraging advanced analytics and data insights. I’m thrilled to join the Board of Directors and to collaborate with an exceptional leadership team who have brought a truly innovative, differentiated technology to market.”
Yoav Tzruya , General Partner, JVP : “As experienced investors in the data and analytics, with proven successes such as Qlik, which was led by JVP’s founder & chairperson, Erel Margalit, from early-stage to post-IPO, we are happy to continue and support Pyramid Analytics.
“Analytics solutions, and especially BI systems, have struggled for more than 2 decades, with the promise on delivering true enterprise-wide decision-support capabilities. Today, such solutions are further crippled, coming up short on the support for diverse and distributed data sources, ever-increasing quantities of data, intuitive user experience, while providing needed enterprise capabilities. Pyramid Analytics is the only solution that brings decision intelligence capabilities for anyone – from C-suite to the front-line – to make faster, more intelligent decisions.”
Haim Sadger , Partner, Sequoia Capital: “Sequoia Capital first invested in Pyramid nearly a decade ago. Over this time, the Pyramid leadership team has turned their vision for giving anyone in an organization the power of data and analytics to make faster, more intelligent decisions into reality. Technology innovations, customer growth, industry analyst recognition and commercial success have followed. We are proud to deepen our partnership, and we look forward to being part of Pyramid’s next stage of growth.”
Sami Totah , General Partner, Viola Growth: “Pyramid Analytics is well on its way to becoming a global leader in the fast-growing decision intelligence category. With 110% net customer retention rate and nearly 2,500 organizations that use Pyramid to speed up insights, scale adoption, and simplify analytics for more than 1 million people, we are truly excited to support its next steps of growth.”
About Pyramid Analytics
Pyramid is a pioneering decision intelligence platform provider. Decision Intelligence is what’s next in analytics. The Pyramid Decision Intelligence Platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics. More than 1 million decision makers rely on Pyramid to make faster, more intelligent decisions. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital and Viola Growth. Learn more at Pyramid Analytics .
1 Based on total capital commitments managed by H.I.G. Capital and affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
